Cisplatin, Cyclophosphamide, Methotrexate, and 5-Fluorouracil (PCMF) as First Line Therapy of Metastatic Triple Negative Breast Cancer (MTNBC) in Patients Previously Treated with Adjuvant Anthracyclines and Taxanes: Retrospective Analysis

Triple Negative ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Previously Treated

Assessment of optimal choice as first-line therapy for patients with triple-negative breast cancer: a Bayesian analysis

10.37766/inplasy2021.8.0030 ◽

2021 ◽

Author(s):

Yiqun Han ◽

◽

Jiayu Wang ◽

Binghe Xu

Keyword(s):

Breast Cancer ◽

Bayesian Analysis ◽

Triple Negative ◽

Optimal Choice ◽

First Line ◽

First Line Therapy ◽

Abstract PS12-28: Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)

10.1158/1538-7445.sabcs20-ps12-28 ◽

2021 ◽

Author(s):

Peter Schmid ◽

Peter Savas ◽

Enrique Espinosa ◽

Valentina Boni ◽

Antoine Italiano ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Phase 1B

Abstract OT1-01-06: A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)

10.1158/1538-7445.sabcs15-ot1-01-06 ◽

2016 ◽

Cited By ~ 7

Author(s):

L Emens ◽

S Adams ◽

S Loi ◽

P Schmid ◽

A Schneeweiss ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Triple Negative ◽

Phase Iii ◽

First Line ◽

First Line Therapy ◽

Abstract P2-15-09: Systemic corticosteroid use in patients with metastatic triple-negative breast cancer treated with first-line therapy in the United States

10.1158/1538-7445.sabcs19-p2-15-09 ◽

2020 ◽

Author(s):

MK Downer ◽

Patricia Luhn ◽

David Miles ◽

Matthew Kent ◽

Kenneth Russell ◽

...

Keyword(s):

Breast Cancer ◽

United States ◽

Triple Negative ◽

Systemic Corticosteroid ◽

The United States ◽

First Line ◽

First Line Therapy ◽

348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.450 ◽

2020 ◽

Vol 31 ◽

pp. S386-S387

Author(s):

D. Eiger ◽

C. Maurer ◽

M. Brandao ◽

P.G. Aftimos ◽

K. Punie ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Triple Negative ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Trial Testing

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)70064-1 ◽

2015 ◽

Vol 16 (4) ◽

pp. 436-446 ◽

Cited By ~ 113

Author(s):

Xi-Chun Hu ◽

Jian Zhang ◽

Bing-He Xu ◽

Li Cai ◽

Joseph Ragaz ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Multicentre Phase ◽

First Line Therapy ◽

Updated survival data and biomarker assessment of the CBCSG006 trial: A randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1093 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1093-1093

Author(s):

Jian Zhang ◽

Ying Lin ◽

Xi-Chun Hu ◽

Wentao Yang ◽

Xiangjie Sun ◽

...

Keyword(s):

Breast Cancer ◽

Survival Data ◽

Triple Negative ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

First Line Therapy ◽

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30450-3 ◽

2017 ◽

Vol 18 (10) ◽

pp. 1360-1372 ◽

Cited By ~ 147

Author(s):

Sung-Bae Kim ◽

Rebecca Dent ◽

Seock-Ah Im ◽

Marc Espié ◽

Sibel Blau ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase 2 ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Phase 2 Trial ◽

Faculty Opinions recommendation of Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734230835.793559070 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Preliminary Data ◽

Triple Negative ◽

Phase 2 ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study

5073 POSTER Bevacizumab (Bev) Combined With Paclitaxel (Pac) as First-line Therapy for Metastatic Triple-negative Breast Cancer (TNBC) -Analysis of 147 Patients (pts) Treated in Routine Oncology Practice in Germany

European Journal of Cancer ◽

10.1016/s0959-8049(11)71515-5 ◽

2011 ◽

Vol 47 ◽

pp. S352 ◽

Cited By ~ 1

Author(s):

A. Schneeweiss ◽

F. Foerster ◽

W. Hollburg ◽

H. Tesch ◽

P. Klare ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Oncology Practice